H W Schytz1, T Wienecke, L T Jensen, J Selb, D A Boas, M Ashina. 1. Danish Headache Center and Department of Neurology Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Glostrup, Denmark. henrikschytz@dadlnet.dk
Abstract
BACKGROUND AND PURPOSE: It is important to find a reliable and bedside method, which can estimate the cerebral blood flow (CBF) of patients in clinical settings. Estimation of CBF by calculating a blood flow index (BFI) using continuous wave near-infrared spectroscopy (CW-NIRS) and indocyanine green (ICG) as an i.v. tracer has been proposed to be a feasible and promising method. To validate if the BFI method can detect relative changes in CBF we compared data with the established method (133)Xenon single photon emission computer tomography ((133)Xe-SPECT). METHODS: Ten healthy subjects were investigated before and after a bolus of acetazolamide. NIRS data were obtained using a multi source detector separation configuration in order to assess a corrected BFI (BFI(corr)) value, which attempts to eliminate contamination of skin blood flow. RESULTS: Data obtained showed no significant correlation between CBF changes measured by (133)Xe-SPECT and BFI(corr) (0.133, P = 0.732). After acetazolamide, a 49% increase in CBF was detected using the (133)Xe-SPECT method, whereas no changes in any ICG variables were observed after acetazolamide. CONCLUSION: The study shows that it is not possible to obtain reliable BFI data, which reflect changes in CBF after acetazolamide infusion, using the CW-NIRS and ICG method.
BACKGROUND AND PURPOSE: It is important to find a reliable and bedside method, which can estimate the cerebral blood flow (CBF) of patients in clinical settings. Estimation of CBF by calculating a blood flow index (BFI) using continuous wave near-infrared spectroscopy (CW-NIRS) and indocyanine green (ICG) as an i.v. tracer has been proposed to be a feasible and promising method. To validate if the BFI method can detect relative changes in CBF we compared data with the established method (133)Xenon single photon emission computer tomography ((133)Xe-SPECT). METHODS: Ten healthy subjects were investigated before and after a bolus of acetazolamide. NIRS data were obtained using a multi source detector separation configuration in order to assess a corrected BFI (BFI(corr)) value, which attempts to eliminate contamination of skin blood flow. RESULTS: Data obtained showed no significant correlation between CBF changes measured by (133)Xe-SPECT and BFI(corr) (0.133, P = 0.732). After acetazolamide, a 49% increase in CBF was detected using the (133)Xe-SPECT method, whereas no changes in any ICG variables were observed after acetazolamide. CONCLUSION: The study shows that it is not possible to obtain reliable BFI data, which reflect changes in CBF after acetazolamide infusion, using the CW-NIRS and ICG method.
Authors: Felix Gora; Samantha Shinde; Clare E Elwell; John C Goldstone; Mark Cope; David T Delpy; Martin Smith Journal: J Neurosurg Anesthesiol Date: 2002-07 Impact factor: 3.956
Authors: Henrik W Schytz; Song Guo; Lars T Jensen; Moshe Kamar; Asaph Nini; Daryl R Gress; Messoud Ashina Journal: Neurocrit Care Date: 2012-08 Impact factor: 3.210
Authors: Otto M Henriksen; Christina Kruuse; Jes Olesen; Lars T Jensen; Henrik B W Larsson; Steffen Birk; Jakob M Hansen; Troels Wienecke; Egill Rostrup Journal: J Cereb Blood Flow Metab Date: 2013-02-13 Impact factor: 6.200
Authors: Aysegul Ergin; Mei Wang; Jane Y Zhang; Jeffrey N Bruce; Robert L Fine; Irving J Bigio; Shailendra Joshi Journal: J Neurooncol Date: 2011-10-01 Impact factor: 4.130
Authors: Daniel Milej; Lian He; Androu Abdalmalak; Wesley B Baker; Udunna C Anazodo; Mamadou Diop; Sudipto Dolui; Venkaiah C Kavuri; William Pavlosky; Lin Wang; Ramani Balu; John A Detre; Olivia Amendolia; Francis Quattrone; W Andrew Kofke; Arjun G Yodh; Keith St Lawrence Journal: J Cereb Blood Flow Metab Date: 2019-09-09 Impact factor: 6.960